Terrie Curran Phathom Pharmaceuticals, Inc. (PHAT) insider trading activity

Terrie Curran is President and Chief Executive of Phathom Pharmaceuticals, Inc.. Currently has a direct ownership of 360,465 shares of PHAT, which is worth approximately $2.36 Million. The most recent transaction as insider was on Jan 21, 2025, when has been sold 19,109 shares (Common Stock) at a price of $6.59 per share, resulting in proceeds of $125,928. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 360K

4.57% 3M change

15.62% 12M change

Total Value Held $2.36 Million

Terrie Curran Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 21 2025	SELL Open market or private sale	$125,928 $6.59 p/Share	19,109 Reduced 5.03%	360,465 Common Stock
Jul 15 2024	SELL Open market or private sale	$396,698 $11.72 p/Share	33,848 Reduced 8.22%	377,734 Common Stock
Mar 22 2024	SELL Open market or private sale	$153,512 $9.11 p/Share	16,851 Reduced 3.94%	410,784 Common Stock
Nov 01 2023	BUY Grant, award, or other acquisition	-	37,500 Added 8.07%	427,171 Common Stock
Jul 14 2023	BUY Grant, award, or other acquisition	-	200,000 Added 33.92%	389,671 Common Stock
Apr 06 2023	BUY Open market or private purchase	$101,026 $7.82 p/Share	12,919 Added 6.42%	188,290 Common Stock
Mar 01 2023	SELL Open market or private sale	$12,263 $8.54 p/Share	1,436 Reduced 0.81%	175,371 Common Stock
Jan 20 2023	SELL Open market or private sale	$47,732 $8.2 p/Share	5,821 Reduced 3.19%	176,807 Common Stock
Jan 19 2023	BUY Grant, award, or other acquisition	-	97,500 Added 34.81%	182,628 Common Stock
Nov 21 2022	SELL Open market or private sale	$14,649 $9.6 p/Share	1,526 Reduced 1.79%	83,720 Common Stock
Sep 01 2022	BUY Grant, award, or other acquisition	-	7,500 Added 8.09%	85,246 Common Stock
May 19 2022	BUY Grant, award, or other acquisition	-	12,000 Added 13.54%	76,595 Common Stock
May 13 2022	BUY Open market or private purchase	$151,905 $7.41 p/Share	20,500 Added 24.09%	64,595 Common Stock
Jan 19 2022	BUY Grant, award, or other acquisition	-	41,250 Added 48.33%	44,095 Common Stock
Mar 22 2021	SELL Open market or private sale	$502,658 $43.66 p/Share	11,513 Reduced 100.0%	0 Common Stock
Mar 22 2021	BUY Exercise of conversion of derivative security	$80,015 $6.95 p/Share	11,513 Added 50.0%	11,513 Common Stock

Also insider at

ARQT

Arcutis Biotherapeutics, Inc. Healthcare

Director

MYOV

Myovant Sciences Ltd. Healthcare

Director

Terrie Curran

President and Chief Executive

Florham Park, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PHAT shares.

Notify only if

Value

Insider Trading

Get notified when an Phathom Pharmaceuticals, Inc. insider buys or sells PHAT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Phathom Pharmaceuticals, Inc.

Track Activities on PHAT

Account